CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Hetero Labs against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Jul 24, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Eliglustat (Genz 112638) As Inhibitor Of Glucosylceramide Synthase For Use In A Method Of Treating Fabry'S Or Gaucher'S Disease, The Method Comprising Adjusting The Individual Therapeutical Dose To The P-450 Metabolism Of The PatientGENZYMEMay 14, 2020

Top competitors of Hetero Labs

List of top competitors of Hetero Labs based on patent oppositions.